ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer

SUPPLEMENTARY FIGURES AND TABLE Supplementary
: Dynamics of ERCC1-positivity in the course of platinum-based chemotherapy. This analysis refers to the prognostic relevance of ERCC1-transcripts alone, irrespectively of the Adnatest transcript markers EpCAM, MUC-1 or CA-125. The pie chart shows a stratification of the study cohort (n=65) into different subgroups, according to the dynamics of ERCC1-positivity (ERCC1 + ) before surgery and after chemotherapy. Beside the group of patients, who were negative for ERCC1 throughout treatment (ERCC1 + neg-neg), we observed patients, who became negative after chemotherapy (ERCC1 + pos-neg), patients with newly acquires positivity after chemotherapy (ERCC1 + neg-pos) or persistently positive patients (ERCC1 + pos-pos). Percentages and absolute patient numbers are indicated. Figure S2 : ROC analysis for the determination of ERCC1 sensitivity and specificity. Blood samples of 20 healthy donors and 99 patients with primary ovarian cancer were analyzed for CTCs with the AdnaTest OvarianCancer and for ERCC1 expression applying densitometric fagment quantification using the Agilent Bioanalyzer 2100. The resulting data were checked for sensitivity and specificity. A cut off value was determined using a ROC analysis. At a cut-off value of 0.17 ng/μl 95% specificity was reached and the corresponding clinical sensitivity was 46.5%. A slightly higher cut-off at 0.2 ng/μl was, however, chosen as kind of a security measure. The table summarizes univariate analysis according to the Kaplan-Meier curves (Figure 2 , 4, 5). The absolute number of patients in each subgroup at a risk of 0%, 25%, 50%, 75% and 100% is indicated for each case.
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